Literature DB >> 15029459

68Ga-labelled DOTA-derivatised peptide ligands.

G-J Meyer1, H Mäcke, J Schuhmacher, W H Knapp, M Hofmann.   

Abstract

68Ge/68Ga generators provide cyclotron-independent access to positron emission tomography (PET) radiopharmaceuticals. We describe a system which allows the safe and efficient handling of 68Ge/68Ga generator eluates for labelling of DOTA-derivatised peptide ligands. The system comprises concentration and purification of the 68Ga eluate as well as labelling and purification steps for peptides, and can be used with different 68Ge/68Ga generator types. The suitability and efficiency were tested with two different DOTA-derivatised somatostatin derivatives and a DOTA-derivatised bombesin derivative. Amounts of 10-20 nmol of the peptides were sufficient and resulted in labelling yields of 50% for all peptides. The built-in safety precautions have proven to be appropriate in allowing use of the method for routine clinical applications. The system was set up and operated in a "hot lab" by personnel with no previous experience in the preparation of PET radiopharmaceuticals.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15029459     DOI： 10.1007/s00259-004-1486-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  6 in total

1.  A new 68Ge/68Ga generator system using an organic polymer containing N-methylglucamine groups as adsorbent for 68Ge.

Authors:  M Nakayama; M Haratake; M Ono; T Koiso; K Harada; H Nakayama; S Yahara; Y Ohmomo; Y Arano
Journal:  Appl Radiat Isot       Date:  2003-01       Impact factor: 1.513

2.  Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.

Authors:  M Hofmann; H Maecke; R Börner; E Weckesser; P Schöffski; L Oei; J Schumacher; M Henze; A Heppeler; J Meyer; H Knapp
Journal:  Eur J Nucl Med       Date:  2001-10-31

3.  DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.

Authors:  Damian Wild; Jörg S Schmitt; Mihaela Ginj; Helmut R Mäcke; Bert F Bernard; Eric Krenning; Marion De Jong; Sandra Wenger; Jean-Claude Reubi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236

4.  A method for the preparation and quality control of 68Ga radiopharmaceuticals.

Authors:  D J Hnatowich
Journal:  J Nucl Med       Date:  1975-08       Impact factor: 10.057

5.  A new generator for ionic gallium-68.

Authors:  C Loc'h; B Mazièré; D Comar
Journal:  J Nucl Med       Date:  1980-02       Impact factor: 10.057

6.  Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.

Authors:  M de Jong; W H Bakker; E P Krenning; W A Breeman; M E van der Pluijm; B F Bernard; T J Visser; E Jermann; M Béhé; P Powell; H R Mäcke
Journal:  Eur J Nucl Med       Date:  1997-04
  6 in total
  47 in total

Review 1.  Feasibility and availability of ⁶⁸Ga-labelled peptides.

Authors:  Clemens Decristoforo; Roger D Pickett; Alfons Verbruggen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

2.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Authors:  Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10       Impact factor: 9.236

3.  Radiolabelling DOTA-peptides with 68Ga.

Authors:  Wouter A P Breeman; Marion de Jong; Erik de Blois; Bert F Bernard; Mark Konijnenberg; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-18       Impact factor: 9.236

4.  A convenient route to [68Ga]Ga-MAA for use as a particulate PET perfusion tracer.

Authors:  Carla J Mathias; Mark A Green
Journal:  Appl Radiat Isot       Date:  2008-06-11       Impact factor: 1.513

5.  Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.

Authors:  S Van Binnebeek; B Vanbilloen; K Baete; C Terwinghe; M Koole; F M Mottaghy; P M Clement; L Mortelmans; K Bogaerts; K Haustermans; K Nackaerts; E Van Cutsem; C Verslype; A Verbruggen; C M Deroose
Journal:  Eur Radiol       Date:  2015-07-12       Impact factor: 5.315

6.  Development and Evaluation of User-Friendly Single Vial DOTA-Peptide Kit Formulations, Specifically Designed for Radiolabelling with 68Ga from a Tin Dioxide 68Ge/68Ga Generator.

Authors:  Deidré Prince; Daniel Rossouw; Claudia Davids; Sietske Rubow
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

7.  Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma.

Authors:  Lihui Wei; Yubin Miao; Fabio Gallazzi; Thomas P Quinn; Michael J Welch; Amy L Vāvere; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2007-09-04       Impact factor: 2.408

8.  A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent.

Authors:  Karl Plössl; Rajesh Chandra; Wenchao Qu; Brian P Lieberman; Mei-Ping Kung; Rong Zhou; Bin Huang; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

9.  Fast 18F labeling of a near-infrared fluorophore enables positron emission tomography and optical imaging of sentinel lymph nodes.

Authors:  Richard Ting; Todd A Aguilera; Jessica L Crisp; David J Hall; William C Eckelman; David R Vera; Roger Y Tsien
Journal:  Bioconjug Chem       Date:  2010-10-20       Impact factor: 4.774

10.  Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours.

Authors:  M de Visser; H F Bernard; J L Erion; M A Schmidt; A Srinivasan; B Waser; J C Reubi; E P Krenning; M de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-08       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.